These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26844708)

  • 41. A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers.
    Abdollahian M; Das TK
    IEEE J Biomed Health Inform; 2015 Mar; 19(2):720-7. PubMed ID: 24771600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
    Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
    Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
    Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C; Lyon L; Conell C; Littell RD; Powell CB
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
    Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
    J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prophylactic salpingectomy or salpingo-oophorectomy as an ovarian cancer prevention?].
    Chene G; Lamblin G; Le Bail-Carval K; Chabert P; Golfier F; Dauplat J; Deligdisch L; Penault-Llorca F; Mellier G
    Presse Med; 2015 Mar; 44(3):317-23. PubMed ID: 25578546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
    Bancroft EK; Locke I; Ardern-Jones A; D'Mello L; McReynolds K; Lennard F; Barbachano Y; Barwell J; Walker L; Mitchell G; Dorkins H; Cummings C; Paterson J; Kote-Jarai Z; Mitra A; Jhavar S; Thomas S; Houlston R; Shanley S; Eeles RA
    J Med Genet; 2010 Jul; 47(7):486-91. PubMed ID: 20472659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    Blok F; Roes EM; van Leenders GJ; van Beekhuizen HJ
    BMC Cancer; 2016 Jan; 16():18. PubMed ID: 26768420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.
    Morice P; Pautier P; Delaloge S; Spatz A; Chompret A
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):251-4. PubMed ID: 15063971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
    Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
    Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
    Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
    J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk.
    Arts-de Jong M; Maas AH; Massuger LF; Hoogerbrugge N; de Hullu JA
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):159-71. PubMed ID: 24529552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
    Cibula D; Zikan M; Dusek L; Majek O
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.